KETOFEN Sterile Solution is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in horses. The product is an FDA-approved non-narcotic, nonsteroidal anti-inflammatory agent with analgesic and antipyretic properties.
As part of the trusted equine pain and sedation portfolio from Zoetis, KETOFEN is safe and effective against equine pain and inflammation. Hoof pain associated with chronic laminitis is significantly reduced for up to six hours with KETOFEN.
- FDA-approved non-narcotic, nonsteroidal anti-inflammatory agent recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in horses
- Significantly reduces hoof pain associated with chronic laminitis for up to six hours
- Showed significant intra-articular anti-inflammatory activity in an experimentally induced acute carpal synovitis model
- Therapeutically equivalent to flunixin meglumine in the alleviation of pain in carpal model of arthritis3
- NSAID of the propionic acid class that includes ibuprofen, naproxen and fenoprofen.
- 1 mg/lb. (1 mL/100 lbs.) of body weight, once daily
- Administer by intravenous injection
- May be repeated for up to five days
- Onset of activity is within two hours with peak response by 12 hours and still measurable at 24 hours
- 50-mL vial
- 100-mL vial
- 250-mL vial
There are no known contraindications to this drug when used as directed. Intra-arterial injection should be avoided. Do not use in a horse if it has previously shown hypersensitivity to ketoprofen.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
For intravenous use in horses only.
This product should not be used in breeding animals since the effects of KETOFEN on fertility, pregnancy or fetal health in horses have not been determined.
Do not exceed the stated dose or the duration of treatment. Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, where there is evidence of a blood dyscrasia or hypersensitivity to the product. Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use can not be avoided, animals may require a reduced dosage and careful management.